Recombinant CD3 (Teplizumab Biosimilar) anticorps

N° du produit ABIN7795117

Cet anticorps anti-CD3 (Teplizumab Biosimilar) Monoclonal Humanized (ABIN7795117) détecte spécifiquement CD3 (Teplizumab Biosimilar) dans FACS et in vivo. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant CD3 (Teplizumab Biosimilar) anticorps (ABIN7795117)

Antigène: CD3 (Teplizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp CD3 (Teplizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD3 (Teplizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Teplizumab Biosimilar, Human CD3e Monoclonal Antibody

Attributs du produit: Teplizumab biosimilar uses the same protein sequences as the therapeutic antibody teplizumab (humanized OKT3). A fully human monoclonal antibody that binds to CD3 epsilon of the T cell receptor-CD3 complex, teplizumab (humanized OKT-3) is used to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human CD3e

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur CD3 (Teplizumab Biosimilar)

Antigène: CD3 (Teplizumab Biosimilar)

Autre désignation: Teplizumab Biosimilar

Classe de substances: Biosimilar